Aubrey Capital Management Ltd Sells 13,216 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Aubrey Capital Management Ltd decreased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 51.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,243 shares of the biopharmaceutical company’s stock after selling 13,216 shares during the period. Aubrey Capital Management Ltd’s holdings in Royalty Pharma were worth $346,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Swedbank AB increased its holdings in Royalty Pharma by 30.6% during the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock worth $285,151,000 after purchasing an additional 2,533,570 shares in the last quarter. Canada Pension Plan Investment Board raised its position in Royalty Pharma by 5.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock valued at $28,051,000 after buying an additional 45,839 shares during the last quarter. Tidal Investments LLC lifted its stake in Royalty Pharma by 28.2% during the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 19,834 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Royalty Pharma by 171.1% during the 3rd quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock worth $2,777,000 after acquiring an additional 64,057 shares during the last quarter. Finally, Summit Global Investments bought a new stake in shares of Royalty Pharma in the 3rd quarter worth $735,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on RPRX. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Citigroup cut their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, The Goldman Sachs Group increased their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $25.85 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The business’s 50 day simple moving average is $27.60 and its 200 day simple moving average is $27.49. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66. The company has a market cap of $15.34 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 3.80 and a beta of 0.47.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.25%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.